CD34 and neutropenia: To extend our previous work, we examined the effects of several cell-permeable NE inhibitors on NE proteolytic activity and myeloid differentiation of CD34+ cells derived from patients with ELANE associated neutropenia, and performed molecular docking studies of the inhibitors with wild-type and mutant NE.